<DOC>
	<DOCNO>NCT01564368</DOCNO>
	<brief_summary>RATIONALE : Imaging procedure , diffusion-weighted magnetic resonance imaging ( DWI ) dynamic contrast-enhanced magnetic resonance imaging ( DCE-MRI ) , may help evaluate well patient breast cancer respond treatment . PURPOSE : This research trial study DWI DCE-MRI assess treatment response patient breast cancer undergo neoadjuvant chemotherapy .</brief_summary>
	<brief_title>DWI Assessing Treatment Response Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine change tumor apparent diffusion coefficient ( ADC ) value measure treatment timepoint baseline predictive pathologic complete response ( pCR ) . Secondary - To determine combined measurement change tumor ADC value , change tumor volume , change peak signal-enhancement ratio ( SER ) predictive pCR . - To investigate relative effectiveness individual measurement , change tumor ADC value , change tumor volume , change peak SER predict pCR experimental treatment arm . - To assess test-retest reproducibility ADC metric apply breast tumor . OUTLINE : This multicenter study . Patients undergo diffusion-weighted magnetic resonance imaging ( DWI ) baseline , week 3 neoadjuvant paclitaxel regimen , prior completion 4 course neoadjuvant chemotherapy . Patients undergo surgery . Patients undergo DWI prior contrast administration dynamic contrast-enhanced magnetic resonance imaging ( DCE-MRI ) . After completion treatment procedure , patient follow 5 year I-SPY 2 TRIAL .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Meets ISPY 2 TRIAL inclusion criterion Highrisk recurrent disease PATIENT CHARACTERISTICS : Able tolerate imaging require protocol PRIOR CONCURRENT THERAPY : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>stage II breast cancer</keyword>
	<keyword>stage IIIA breast cancer</keyword>
	<keyword>stage IIIB breast cancer</keyword>
	<keyword>stage IIIC breast cancer</keyword>
	<keyword>stage IV breast cancer</keyword>
	<keyword>HER2-negative breast cancer</keyword>
	<keyword>HER2-positive breast cancer</keyword>
</DOC>